- Prophylaxis of invasiveAspergillus and disseminated candidiasis in severely immunocompromised hosts
- Such as hematopoietic stem cell transplant recipients with graft vs. host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy- all formulations.
- Treatment of oropharyngeal candidiasis, including itraconazole and/or fluconazole refractory cases- oral suspension only.
NON-FDA APPROVED USES
- Treatment of invasive fungal infections (aspergillosis, histoplasmosis, coccidioidomycosis, candidiasis) in patients who are intolerant to, or whose infections are refractory to standard therapy.
- Maintenance therapy for Mucorales in patients whose infection has been controlled with standard therapy (e.g., liposomal amphotericin B +/- surgery)
- Alternative treatment of infections due to hyaline fungi (e.g. Scedosporium spp., Acremonium spp., Scopulariopsis spp., Purpureocillium spp.).
- Posaconazole may be effective in combination with surgery for eumycotic mycetoma (localized fungal infections that may involve cutaneous and subcutaneous tissue, fascia and bone).
- Based on in-vitro data and limited clinical experience, posaconazole may be effective for infections due to certain dematiaceous fungi.
There's more to see -- the rest of this topic is available only to subscribers.